高级检索
当前位置: 首页 > 详情页

The effectiveness and safety of the rapid titration strategy of background controlled-release oxycodone hydrochloride for patients with moderate-to-severe cancer pain: A retrospective cohort study

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE ◇ 预警期刊

机构: [1]Department of Head and Neck/Thoracic Medical Oncology, The First People's Hospital of Foshan, Foshan, China. [2]Department of Cadre Medical Section, Yunnan Cancer Hospital & the Third Affiliated Hospital of Kunming Medical University & Yunnan Cancer Center, Kunming, China. [3]Department of Oncology, Hubei Cancer Hospital, Wuhan, China. [4]Department of Pain Management, Yunnan Cancer Hospital & the Third Affiliated Hospital of Kunming Medical University & Yunnan Cancer Center, Kunming, China. [5]Department of Oncology, Tangdu Hospital of Air Force Medical University, Xi'an, China. [6]Department of Thoracic Radiotherapy, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, Cancer Hospital Affiliate to School of Medicine, UESTC, Chengdu, China. [7]Department of Oncology, Cancer Hospital of Shantou University Medical College, Shantou, China. [8]Department of Oncology, Changsha Hospital of Traditional Chinese Medicine (Changsha Eighth Hospital), Changsha, China. [9]Cancer Center, Xiehe Hosptial Tongji Medical College Huazhong University of Science and Technology, Wuhan, China. [10]Department of Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, China. [11]Department of Oncology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China. [12]Department of Oncology, Tongji Hospital, Tongji Medical College of Huazhong University of Science and Technology, Shanghai, China. [13]Department of Oncology, Chengdu Fifth People's Hospital, Chengdu, China. [14]Department of Oncology, The Central Hospital of Xiangyang, Chengdu, China. [15]Department of Oncology, Guangzhou Red Cross Hospital, Guangzhou, China. [16]Department of Oncology, The First Hospital of Lanzhou University, Lanzhou, China. [17]Department of Hematology and Oncology, Hospital 452 of PLA, Chengdu, China. [18]Department of Oncology, Chongqing Traditional Chinese Medicine Hospitai & No. 4 Clinical Medicine School of Chengdu University of TCM, Chongqing, China. [19]Respiratory Department, Xinjiang Cancer Hospital, Urumqi, China. [20]Department of Oncology, PLA Army 74 Group Army Hospital, Guangzhou, China. [21]Department of Oncology, Jinshazhou Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China. [22]Department of Oncology, Peking University Shenzhen Hospital, Shenzhen, China. [23]Department of Oncology, The Second Affiliated Hospital of Hainan Medical University, Haikou, China. [24]Department of Oncology, Fuzhou PLA General Hospital, Fuzhou, China. [25]Department of Oncology, The Central Hospital of Wuhan, Wuhan, China. [26]Department of Integrated Chinese and Western Medicine, Shaanxi Cancer Hospital Affiliated to Medical College of Xi'an Jiaotong University, Xi'an, China.
出处:
ISSN:

摘要:
Oxycodone hydrochloride is a semisynthetic narcotic analgesic agent. This study aimed to explore optimal titration strategy of controlled-release (CR) oxycodone hydrochloride in patients with cancer pain.258 patients, who used regular strong opioids (morphine and CR oxycodone hydrochloride) for cancer pain across 25 three grade class hospitals in China during January 15th 2017 to April 30th 2017, were retrospectively studied. The patients were divided into 4 groups according to treatment regimens titrated. The pain remission rate and numeric rating scale (NRS) of cancer pain was recorded at 0, 12, 24, 36, 48, 60, 72 h after opioid titration. The incidence of adverse events (AEs) with therapy were also observed.12 h after treatment, pain remission rate of Group B, C and D was significantly higher (P < 0.001) than Group A. For the complete remission rate, there were also significant differences among the four groups (P < 0.001). No significant difference was found among four groups for pain remission rate at 24, 72 h after treatment. Multiple comparison of NRS scores showed that the both Group B and C varied significantly with Group D (P = 0.028, P = 0.05, respectively), showing superior analgesic effect over Group D. AEs were significantly different among groups (P < 0.01), with the most frequent AEs in Group A, lowest in Group B.The rapid titration strategy of background CR oxycodone hydrochloride was effectiveness and safety in patients with moderate-to-severe cancer pain.Copyright © 2022 Feng, Wang, Ran, Mao, Zhang, Wang, Lin, Wang, Hu, Liao, Zhang, Chu, Xiong, Yi, Yi, Ma, Sun, Meng, Liu, Zhou, Zheng, Wang, Lin, Fang, Li and Wu.

语种:
被引次数:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2022]版:
大类 | 3 区 医学
小类 | 3 区 医学:内科
最新[2023]版:
大类 | 3 区 医学
小类 | 3 区 医学:内科
JCR分区:
出版当年[2022]版:
Q2 MEDICINE, GENERAL & INTERNAL
最新[2023]版:
Q1 MEDICINE, GENERAL & INTERNAL

影响因子: 最新[2023版] 最新五年平均 出版当年[2022版] 出版当年五年平均 出版前一年[2021版] 出版后一年[2023版]

第一作者:
第一作者机构: [1]Department of Head and Neck/Thoracic Medical Oncology, The First People's Hospital of Foshan, Foshan, China.
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:43375 今日访问量:0 总访问量:3120 更新日期:2024-09-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 四川省肿瘤医院 技术支持:重庆聚合科技有限公司 地址:成都市人民南路四段55号